Athersys, Inc / New (ATHX) Files Form 4 Insider Selling : William Jr Lehmann Sells 25,000 Shares

Athersys, Inc / New (ATHX): William Jr Lehmann , President and COO of Athersys, Inc / New sold 25,000 shares on Jun 20, 2016. The Insider selling transaction was reported by the company on Jun 21, 2016 to the Securities and Exchange Commission. The shares were sold at $2.17 per share for a total value of $54,334.50 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 21, 2016, William Jr Lehmann (President and COO) sold 25,000 shares at $2.41 per share price.On Sep 21, 2015, John J Harrington (Exec Vice Pres and CSO) sold 8,150 shares at $1.36 per share price.Also, On Sep 21, 2015, Bokkelen Gil Van (Chairman and CEO) sold 9,500 shares at $1.36 per share price.On Jun 19, 2015, Robert J Deans (Executive Vice President) sold 5,080 shares at $1.23 per share price.

Athersys: On Monday, Jun 20, 2016 heightened volatility was witnessed in Athersys which led to swings in the share price. The shares opened for trading at $2.18 and hit $2.21 on the upside , eventually ending the session at $2.19, with a gain of 1.39% or 0.03 points. The heightened volatility saw the trading volume jump to 4,19,909 shares. The 52-week high of the share price is $2.9 and the company has a market cap of $185 M . The 52-week low of the share price is at $0.94.

Athersys Money Flow Index Chart

Athersys Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy is being evaluated in multiple clinical trials. Its current clinical development programs are focused on treating inflammatory and immune disorders neurological conditions cardiovascular disease and other conditions. It is also identifying and developing small molecule compounds with applications in indications such as obesity related metabolic conditions and neurological conditions. It is engaged in the preparation stages for clinical studies in other targeted areas including the treatment of ARDS. Its current programs include Ischemic Stroke Acute Myocardial Infarction Acute Respiratory Distress Syndrome Hematopoietic Stem Cell Transplant/GvHD and Inflammatory Bowel Disease. In addition to the programs it is also conducting or supporting clinical activity in other areas such as solid organ transplant.

Leave a Reply

Athersys - Is it time to Sell?

Top Brokerage Firms are advising their investors on Athersys. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.